Key result
Levosimendan improves biventricular function and hemodynamics while reducing pulmonary vascular remodeling in preclinical PH models.
Why the study?
Group-2 pulmonary hypertension lacks approved targeted therapies largely due to the absence of reliable preclinical models recapitulating human IpcPH and CpcPH phenotypes, and the mechanisms of action of levosimendan in this condition remain unclear.
Does levosimendan ameliorate pulmonary vascular remodeling, inflammation, and hemodynamic impairment in preclinical rodent models of isolated post-capillary PH (IpcPH) and combined post- and pre-capillary PH (CpcPH)?
Does levosimendan ameliorate pulmonary vascular remodeling, inflammation, and hemodynamic impairment in preclinical rodent models of isolated post-capillary PH (IpcPH) and combined post- and pre-capillary PH (CpcPH)?
Establishes validated rodent models of IpcPH and CpcPH and demonstrates that levosimendan exerts dual inotropic and anti-inflammatory/anti-remodeling effects via NF-κB inhibition in Group-2 pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Should not change CpcPH management; leaves open translation of levosimendan anti-remodeling effects from rodent models.
Aims Pulmonary hypertension (PH) due to left heart disease (Group-2PH) is the most common form of PH and comprises two distinct subtypes: isolated post-capillary-PH (IpcPH) and combined post-and pre-capillary-PH (CpcPH). Despite its high prevalence and poor prognosis, no targeted therapies are currently approved, largely due to the absence of reliable preclinical models that recapitulate these human hemodynamic phenotypes. Levosimendan, a calcium sensitizer with inotropic and vasodilatory properties, has shown promise in early clinical trials for Group-2PH, but its mechanisms of action remain unclear. This study aimed to develop and validate experimental models of IpcPH and CpcPH and to assess the therapeutic effects of levosimendan on pulmonary vascular remodeling, inflammation, and cardiac function to support ongoing clinical translation. Methods and Results In a multicentre preclinical study, we established two rodent models that faithfully replicate the human IpcPH and CpcPH hemodynamic profiles. CpcPH animals exhibited severe pulmonary vascular remodeling, inflammatory cell infiltration, and a distinct pro-proliferative transcriptomic signature, whereas IpcPH animals showed minimal pulmonary vascular involvement. Levosimendan (3 mg/kg/day, 3 weeks) improved biventricular function and pulmonary hemodynamics in both models. In CpcPH, levosimendan additionally reduced pulmonary vascular remodeling, attenuated inflammation, and partially reversed disease-associated transcriptomic reprogramming. Transcription factor enrichment analysis identified NF-κB as a key upstream regulator inhibited by treatment. In a translational extension, nine circulating inflammation-related-proteins differentiated CpcPH from IpcPH patients; among them, TNF, IL-12B, 4E-BP1, NT-3, NGF, FGF21, and FGF23 predicted poor survival. IL-18 and 4E-BP1 were elevated in CpcPH lungs and decreased following levosimendan treatment. Conclusions Inflammation is a major contributor to adverse pulmonary vascular remodeling in CpcPH. Levosimendan improves cardiac performance and mitigates pulmonary vascular inflammation and remodeling, supporting its potential as a dual-action therapeutic agent in Group-2PH. These findings validate novel preclinical models and provide mechanistic evidence reinforcing ongoing clinical evaluation of levosimendan in this condition. Translational perspective Group-2 PH lacks targeted therapies, partly due to the absence of validated preclinical models. We validated models recapitulating human IpcPH and CpcPH and identified inflammation as a key driver of pulmonary vascular remodeling in CpcPH. Levosimendan improved biventricular function and reduced vascular remodeling and inflammation through NF-κB inhibition. Circulating IL-18 and 4E-BP1 reflected disease severity and treatment response. These findings establish robust translational models, reveal inflammatory mechanisms underlying CpcPH, and provide mechanistic evidence supporting ongoing clinical trials of levosimendan as a dual-action therapeutic strategy in Group-2 PH.
No takes yet. Share an insight, caveat, or question.
Abi-Sleimen et al. (2025) studied Group-2 pulmonary hypertension (isolated post-capillary PH [IpcPH] and combined post- and pre-capillary PH [CpcPH]) (n=70). Levosimendan vs. Vehicle treatment via oral gavage was evaluated on Pulmonary vascular remodeling, inflammation, and biventricular/pulmonary hemodynamics in rodent models; all-cause mortality and subtype discrimination in the human translational cohort. Levosimendan improved biventricular function and hemodynamics in both PH models and reduced pulmonary vascular remodeling and NF-κB-driven inflammation in CpcPH rats.
Synapse has enriched 10 related papers. Consider them for comparative context: